Bio-Techne Corporation has announced that Advanced Cell Diagnostics (ACD), a Bio-Techne brand for spatial biology, has set a new standard with the development of a protease-free RNAscope Spatial Multiomics workflow of the next generation.
The newly developed RNAscope spatial multiomics workflow is optimized for the detection of protein and RNA biomarkers on the same slide with unprecedented sensitivity and tissue morphology, compatible with both manual and automated assays. ACD’s novel protease-free RNAscope workflow is integrated into Bio-Techne’s recently announced premium multiomics application on Lunaphore’s COMET platform.
The simultaneous mapping of RNA and protein biomarkers on the same tissue section will enable an unprecedented single-cell view of disease pathology and therapeutic response. ACD’s new innovation represents a significant improvement over existing spatial technologies, which are designed to detect either RNA or protein, not both, and typically lead to degradation of the alternative biomarker type.
By avoiding proteases commonly used in RNA detection, this advanced workflow preserves protein and RNA integrity as well as tissue morphology. This advancement allows for easy quantification of subcellular gene expression and multiomic changes, further simplifying image and data analysis.
„We are proud to achieve another milestone in our spatial multiomics strategy with the development of a novel, protease-free RNAscope workflow. We have been impressed by the overwhelmingly positive feedback from customers who have tested this new workflow with our currently available RNAscope assays on the market, and we look forward to offering this new feature across our entire RNAscope portfolio later this year.“
Kim Kelderman, Chief Operating Officer, Bio-Techne
Bio-Techne’s ACD brand is a pioneer in spatial biology, offering industry-leading single-molecule sensitivity and unparalleled specificity with its patented RNAscope ISH technology for over 10 years. With over 9,500 peer-reviewed publications and more than 50,000 unique probes sold, RNAscope technology has enabled spatial detection of a wide range of RNA subtypes in the industry from research to clinical applications.
The data will be presented at a series of activities at the Advances in Genome Biology and Technology (AGBT) 2024 General Meeting in Orlando, Florida, from February 5th to 8th. Additional data demonstrating technical advancements in the co-detection of RNA with proteins and protein-protein interactions using RNAscope will be presented at AGBT by ACD scientist Ge-Ah Kim, Ph.D., on February 7th at Poster No. 633 titled „Single-slide, in situ multiomic imaging of mRNA, protein, and protein-protein interactions in the tumor immune microenvironment of bladder cancer patients.“